Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13668MR)

This product GTTS-WQ13668MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13668MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4825MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ945MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10959MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ778MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ7006MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ5897MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ11429MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ10769MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW